Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day. The company, ...
Kiss Kiss Bang Bang' and the wasted potential of Val Kilmer: an exploration of why Kilmer's excellent performance didn't lead to a comeback.
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest ...
(NEO) stock saw a modest uptick, ending the day at $14.71 which represents a slight increase of $0.93 or 6.75% from the prior close of $13.78. The stock opened at $14.95 and touched a low of $14.48 ...
Benchmark Co. analyst Bruce Jackson maintained a Hold rating on NeoGenomics (NEO – Research Report) today. The company’s shares closed ...
The power sector is set for record earnings, fueled by rising demand, favourable summer climate, and expansion of India’s ...
GeneDx Corp's 2024 success story: profitability, 100x returns, NICU market expansion, pediatric neurology diagnostics, and ...
16h
Bank of America Securities analyst Michael Ryskin maintained a Hold rating on NeoGenomics (NEO – Research Report) yesterday and set a price ...
Investor's Business Daily on MSN20h
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term GuidanceNeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback